ログイン
言語:

WEKO3

  • トップ
  • ランキング


インデックスリンク

インデックスツリー

  • RootNode

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 050 医学部, 大学院医学系研究科
  2. 0507 学位論文
  3. 博士(医学)

Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group Study

http://hdl.handle.net/10091/17658
http://hdl.handle.net/10091/17658
b7690165-756e-486c-9f4b-6230c77030e5
名前 / ファイル ライセンス アクション
H24Kou939_Tateishi.pdf H24Kou939_Tateishi.pdf (612.7 kB)
Item type 学術雑誌論文 / Journal Article(1)
公開日 2014-06-27
タイトル
タイトル Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group Study
言語
言語 eng
DOI
関連識別子 https://doi.org/10.1007/s12032-012-0450-2
関連名称 10.1007/s12032-012-0450-2
資源タイプ
資源 http://purl.org/coar/resource_type/c_6501
タイプ journal article
著者 Tateishi, Kazunari

× Tateishi, Kazunari

Tateishi, Kazunari

Search repository
Ichiyama, Takashi

× Ichiyama, Takashi

Ichiyama, Takashi

Search repository
Hirai, Kazuya

× Hirai, Kazuya

Hirai, Kazuya

Search repository
Agatsuma, Toshihiko

× Agatsuma, Toshihiko

Agatsuma, Toshihiko

Search repository
Koyama, Shigeru

× Koyama, Shigeru

Koyama, Shigeru

Search repository
Hachiya, Tsutomu

× Hachiya, Tsutomu

Hachiya, Tsutomu

Search repository
Morozumi, Nobutoshi

× Morozumi, Nobutoshi

Morozumi, Nobutoshi

Search repository
Shiina, Takayuki

× Shiina, Takayuki

Shiina, Takayuki

Search repository
Koizumi, Tomonobu

× Koizumi, Tomonobu

Koizumi, Tomonobu

Search repository
出版者
出版者 HUMANA PRESS INC
引用
内容記述 MEDICAL ONCOLOGY. 30(1):45 (2013)
書誌情報 MEDICAL ONCOLOGY

巻 30, 号 1, p. 450, 発行日 2013-03
内容記述
内容記述タイプ Other
内容記述 信州大学博士(医学)・学位論文・平成24年3月31日授与(甲第939号)・立石 一成
内容記述
内容記述タイプ Other
内容記述 The final publication is available at www.springerlink.com.
抄録
内容記述 The clinical efficacy and outcomes of gefitinib therapy as a first-line treatment for elderly patients with non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations were analyzed retrospectively. We analyzed chemotherapy-naive NSCLC patients aged 75 years or older who had EGFR mutations (exon 19 deletion mutation or L858R), who were initially treated with gefitinib (250 mg) once daily in Nagano Prefecture. A total of 55 patients (16 men, 39 women) with a median age of 81.1 years (range; 75-94 years) treated between April 2007 and July 2012 were analyzed. The overall response rate and disease control rate were 72.7 % (95 % confidence interval (CI); 59.5-82.9 %) and 92.7 % (95 % CI; 82.0-97.6 %), respectively. Median progression-free survival and overall survival from the start of gefitinib treatment were 13.8 months (95 % CI; 9.9-18.8 months) and 29.1 months (95 % CI; 22.4 months-not reached), respectively. Two-year survival rate was 59.5 % (95 % CI; 41.0-78.0 %). Major grade 3 toxicities were skin rash (1.8 %) and increased levels of aspartate aminotransferase or alanine aminotransferase (7.3 %). First-line treatment with gefitinib for elderly EGFR-mutated NSCLC patients was effective and well tolerated. The results suggest that first-line gefitinib should be considered as a preferable standard treatment in elderly patients with advanced NSCLC harboring EGFR mutations.
資源タイプ(コンテンツの種類)
出版タイプ
出版タイプ AM
出版タイプResource http://purl.org/coar/version/c_ab4af688f83e57aa
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 13:03:29.220549
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3